Chrysomycin A Derivatives for the Treatment of Multi-Drug-Resistant Tuberculosis
Fan Wu, Jing Zhang, Fuhang Song, Sanshan Wang, Hui Guo, Qi Wei, Huanqin Dai, Xiangyin Chen, Xuekui Xia, Xueting Liu, Lixin Zhang, Jin‐Quan Yu, Xiaoguang Lei
Abstract
, and the mechanism of action of this compound is unknown. To facilitate the mechanism of action and preclinical studies of chrysomycin A, we developed a 10-step, scalable synthesis of the isolate and its two natural congeners polycarcin V and gilvocarcin V. The synthetic sequence was enabled by the implementation of two sequential C-H functionalization steps as well as a late-stage C-glycosylation. In addition, >10 g of the advanced synthetic intermediate has been prepared, which greatly facilitated the synthesis of 33 new analogues to date. The structure-activity relationship was subsequently delineated, leading to the identification of derivatives with superior potency against MDR-TB (MIC = 0.08 μg/mL). The more potent derivatives contained a modified carbohydrate residue which suggests that further optimization is additionally possible. The chemistry we report here establishes a platform for the development of a novel class of anti-TB agents active against drug-resistant pathogens.